This year’s ASCO conference has plenty of data from the CAR-T therapy contenders - but little known Chinese biotech Nanjing Biotech looks to have trumped all the established firms.
A combination of Novartis’ 'next generation' CAR-T drug CTL119 with Janssen and AbbVie's Imbruvica has cleared all signs of chronic lymphocytic leukaemia from eight out of nine patients in
